Session Information
Date: Wednesday, June 22, 2016
Session Title: Parkinson's disease: Cognition
Session Time: 12:00pm-1:30pm
Location: Exhibit Hall located in Hall B, Level 2
Objective: In Parkinson’s disease (PD) in almost all patients at the early stages of developing cognitive impairment.
Background: Study of the degree of cognitive impairment, depending on the level of neuron protein S100B in plasma with various forms of parkinsonism.
Methods: The material of this study was 40 patients with various forms of parkinsonism, 22 patients with PD and 10 patients with vascular parkinsonism (VP) and 8 with parkinsonism+. The study group included 22 patients with PD, including 13 males and 9 women. Duration of the disease – is 0.5 to 8 years. The severity of PD was determined Using standardized rating scale assessment manifestations PD (Unified Parkinson’s disease Rating Scale-UPDRS), the initiate movement disorders. The control group consisted of 9 patients without symptoms of Parkinson’s disease; Determines the content of S100B in the blood serum by enzyme immunoassay performed with specific test systems developed on the basis of appropriate monoclonal antibodies on the analyzer Hospitex Diagnostics, Italy according to the instructions supplied with the kit. The degree of cognitive impairment was assessed by neuropsychological testing.
Results: The results of our study show that when PD in 59.1% of patients experienced mild cognitive impairment (MCI), 22.7% of patients experienced an average cognitive impairment (ACI) and 18.2% of patients had severe cognitive impairment (SCI). When both of these patients plasma protein S100B support height was 110,4±4,7–158,04±2,1–172,2±2,2 ng/l. Vascular parkinsonism respectively light MCI in 50% of patients and breaker failure S100B 240,3±6,5 ng / l, ACI in 20% of patients and breaker failure of protein-313,6±7,6 and when 30% SCI support height protein was 339,8,6±13,2 ng/l. At the parkinsonism+ 50% MCI, 25% FCI and 25% SCI, respectively S100B protein in these patients was 125,8±8,3 -161,9±6,4-236,03±14,3 ng/l.
Conclusions: Parkinsonism degree of cognitive impairment not only depends on the form of the disease, and also depends on the level S100B in plasma.
To cite this abstract in AMA style:
R.J. Matmurodov, K.M. Khalimova, N.S. Rashidova, U. Ergashev, O. Turgunhojayev. Neuron specific protein S100B and cognitive impairment in various forms parkinsonism [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/neuron-specific-protein-s100b-and-cognitive-impairment-in-various-forms-parkinsonism/. Accessed December 11, 2024.« Back to 2016 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/neuron-specific-protein-s100b-and-cognitive-impairment-in-various-forms-parkinsonism/